CytoReason Announces Collaboration with Ferring to Identify Novel Therapeutic Targets in Inflammatory Bowel Disease Using AI Technology

Photo by: Shutterstock
Photo by: Shutterstock

CytoReason’s computational model simulates human disease on a cellular level, and makes clinical trials more focused and accurate over time. To date, six of the world’s top ten pharma companies use CytoReason’s technology to bring the right drug to the right patient at the right price.

מאי 2021

CytoReason, an Israeli company developing a computational model of the human body for faster drug discovery and development, recently announced a collaboration with Ferring Pharmaceuticals.

This is the first collaboration between the two companies, pairing Ferring’s medical expertise with CytoReason’s AI platform to build cell-centered disease models for Inflammatory Bowel Disease (IBD), including Crohn’s and Colitis. CytoReason’s use of computational models of the human body has the potential to help Ferring innovate and accelerate drug discovery while reducing costs. Leveraging an ever-growing library of both public and proprietary molecular data, CytoReason’s technology allows scientists to gain critical information on the body’s functioning, and to address diseases such as IBD at the cellular level. 

CytoReason’s computational model simulates human disease on a cellular level, minimizes the need for animal trials and makes human trials more focused and accurate. 

"We are very excited to be working with the talented team at Ferring," said David Harel, CEO and Co-founder of CytoReason. "Their expertise in gastroenterology, immunology and translational medicine will allow us to better understand the complex nature of IBD, and in turn, to create more accurate models of the disease with our AI technology. Our platform will enable Ferring to develop new drugs for IBD, significantly shorten drug discovery time, dramatically reduce the costs involved, and ultimately help more patients who suffer from the chronic disease."

For more information, visit:

יש לכם רעיון למגזין משלכם? צרו קשר